Key Highlights
- The USPTO granted a U.S. Patent with 36 claims covering stenoparib's twice-daily oral dosing regimen with protection into 2045.
- Claims cover treatment of advanced ovarian cancer and other solid tumors including breast, colon, pancreatic, and prostate cancers.
- The patent complements a previously issued patent covering Allarity's stenoparib-specific DRP companion diagnostic.
- Stenoparib is currently being evaluated in Phase 2 clinical programs in ovarian cancer and small cell lung cancer.
Allarity Therapeutics, Inc. (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company, has announced that the United States Patent and Trademark Office has granted a patent covering stenoparib treatment regimens with protection extending into 2045.
Patent Scope and Claims
The patent, assigned U.S. Patent No. 12,806,205, includes 36 allowed claims covering twice-daily oral administration of stenoparib, including specified dose levels and treatment schedules relevant to the company's clinical development program. The claims encompass methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic, and prostate cancers, as well as patients whose disease has not responded to prior therapies, including other PARP inhibitors.
CEO Thomas Jensen stated that the patent's coverage of the twice-daily dosing strategy is critical as this is the regimen the company intends to advance to pivotal trials. The protection period extending into 2045 is intended to provide a foundation for continued Investment and partnering discussions.
Intellectual Property Strategy
The patent complements Allarity's previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. Together, these patents are designed to support the company's strategy of developing stenoparib alongside a proprietary approach to identifying patients most likely to benefit from the treatment. The DRP methodology uses messenger RNA expression profiles from patient biopsies to generate drug-specific predictive scores.
About Stenoparib
Stenoparib is an orally available small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. Through its inhibition of PARP and the WNT signaling pathway, stenoparib has the potential to provide therapeutic benefit across multiple cancer types. Allarity holds exclusive global rights to develop and commercialize stenoparib, which was originally developed by Eisai Co., Ltd.
Clinical Programs
A Phase 2 protocol evaluating stenoparib in patients with platinum-resistant or platinum-ineligible ovarian cancer has been amended to add patient groups with primary platinum-refractory disease and those with clinically evaluable but non-measurable disease. A separate Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer began enrolling in early 2026 at U.S. Department of Veterans Affairs sites.
Risks and Uncertainties
Patent protection does not guarantee commercial success, and the scope and enforceability of the claims may be challenged. Stenoparib remains in clinical development with uncertain outcomes. The company's ability to advance toward late-stage trials and regulatory approval depends on clinical data, Capital resources, and potential partnerships.






Please wait processing your request...